Fierce Pharma Asia—China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series Anews2021-12-10T07:51:06+00:00December 10th, 2021|Fierce Pharma|
Another Samsung Bioepis? Biocon, Viatris mull merging biosimilar businesses: reportnews2021-12-09T15:59:03+00:00December 9th, 2021|Fierce Pharma|
Amid Aduhelm’s rocky launch, Biogen eyes large-scale layoffs: reportnews2021-12-09T15:58:03+00:00December 9th, 2021|Fierce Pharma|
BioPure set to add 120 jobs at newly completed UK manufacturing sitenews2021-12-09T15:28:09+00:00December 9th, 2021|Fierce Pharma|
Amid consumer spinoff and CEO transition, Johnson & Johnson names new leadership teamnews2021-12-09T15:05:43+00:00December 9th, 2021|Fierce Pharma|
AstraZeneca and other lung cancer specialists join together to emphasize early screeningsnews2021-12-09T14:53:20+00:00December 9th, 2021|Fierce Pharma|
Shanghai Pharma, Syntegon to build lab in China to advance continuous manufacturing technews2021-12-09T14:47:06+00:00December 9th, 2021|Fierce Pharma|
After its $7.6B buyout fell through, Sobi scores NICE backing for rare disease drug Aspavelinews2021-12-09T14:42:15+00:00December 9th, 2021|Fierce Pharma|
Square pumping $74M into Kenya plant as Africa draws more manufacturing interestnews2021-12-09T13:58:55+00:00December 9th, 2021|Fierce Pharma|
AstraZeneca’s COVID therapy becomes first antibody approved for immunocompromised people preexposurenews2021-12-08T22:40:33+00:00December 8th, 2021|Fierce Pharma|
